%20(1).png)
Global healthcare programs are often judged by one simple measure: did they work in every market?
When the answer is no, the immediate reaction is usually to question the solution itself. Perhaps the patient support program wasn't relevant. Perhaps the messaging needed to be localized. Perhaps the market was simply too different.
Sometimes that's true. But just as often, the strategy is sound; the challenge lies in how it is executed.
As discussed in our recent whitepaper, How Pharma Can Use Behavioral Science to Balance Global Strategy with Local Relevance, organizations frequently assume that poor performance in one or two markets means the solution itself needs to be redesigned or localized further. In reality, the underlying strategy may have been entirely correct. The solution simply wasn't implemented in a way that allowed it to succeed.
This distinction matters because redesigning a solution that was fundamentally sound adds unnecessary complexity, delays rollout, and consumes resources that could have been invested in improving adoption. The challenge, therefore, is learning to distinguish between a solution problem and an execution problem.
In this article, we explore how to bridge four of the most common execution gaps that prevent well-designed global healthcare programs from achieving their full potential.
1. Embed the program into everyday clinical practice
Developing a patient support solution is only the first step. The real challenge is ensuring it becomes part of routine clinical practice.
Patient support programs rarely reach patients directly. They typically pass through several layers before creating any impact. Sales representatives need to understand the solution and believe in its value. Healthcare professionals need to know when and how to introduce it. Patients then need to engage with it consistently over time.
At every stage, adoption can break down.
Launching a program is not simply about making it available. Representatives need to incorporate it into already limited conversations with physicians. Healthcare professionals need to adjust established clinical routines. Patients need to build new habits that support treatment adherence.
None of those behaviors happen automatically.
The challenge is compounded by the realities of healthcare delivery. Representatives often have only a handful of interactions with a physician each year, while balancing disease education, product discussions and other priorities. Every additional message competes for attention. Unless the patient support program is clearly integrated into those conversations and perceived as genuinely valuable, it is unlikely to become part of everyday practice.
2. Create local ownership from the outset
Even the strongest global strategy can struggle if local affiliates feel it has been designed for them rather than with them.
It's easy to assume that resistance from local markets reflects disagreement with the strategy itself. In reality, the issue is often far more human. People are naturally more motivated to support something they have helped create than something handed to them fully formed.
Successful implementation depends on more than handing local teams a finished program. It requires involving them early enough for them to understand both the behavioral challenge being addressed and the reasoning behind the proposed solution.
Even the best strategy can lose momentum if local teams don't feel ownership. Without that involvement, affiliates may use different language to describe the same challenge, interpret priorities differently, or simply feel less motivated to champion a solution they had little role in creating.
Involving affiliates early creates a shared vocabulary, builds trust in the underlying behavioral diagnosis, and gives local teams confidence to champion the program within their own organizations. Rather than simply reviewing finished materials, they become active contributors to the strategy itself.
The result is not only better local insight but significantly stronger implementation. When affiliates understand why decisions have been made and feel they have played a role in making them, they are far more likely to support consistent execution across markets.
3. Separate execution problems from strategy problems
One of the biggest risks facing global teams is drawing the wrong conclusion from mixed results.
When a program underperforms in one market, the instinct is often to revisit the solution itself. Should it be redesigned? Should more features be added? Should it be localized further?
Sometimes those changes are justified. Often they are not.
If a global program is succeeding in most markets but struggling in one or two, the issue is more likely to be implementation than strategy. Conversely, if performance is poor across multiple markets, it may be time to revisit the original strategy.
The difficulty is that many organizations simply don't have the visibility to make that distinction.
“Much localization is "adaptation without diagnosis." Teams begin changing assets, rebuilding content, or redesigning programs before establishing whether the underlying behavioral challenge is actually different or whether execution simply failed.”
Sean Gill, Director of Behavior Science, S3 Connected Health
Without a consistent measurement framework, adoption becomes a black box. Leadership may see overall performance figures, but not where engagement begins to break down. Was the solution introduced by healthcare professionals? Did patients activate it? Did they remain engaged? Or did the program never really leave the starting line?
Without answers to these questions, organizations risk investing significant time and money redesigning solutions that were fundamentally sound.
The consequences extend beyond a single market. Every unnecessary rebuild creates duplicated investment, delays implementation, and makes it harder for global teams to compare results and learn what is genuinely working across markets.
4. Focus on adoption long after launch
Launching a global program is a major milestone, but successful adoption depends on everything that happens afterward.
Understandably, organizations devote significant effort to designing the solution, securing approvals, developing content, configuring platforms, and preparing for launch. Yet the operational work that follows often receives far less attention.
This is where many of the decisions that ultimately determine adoption are made.
When should representatives introduce the program? How should they position it? Which materials should support the conversation? At what point in the patient journey should healthcare professionals discuss it? How should the program be incorporated into existing workflows?
Crucially, once launched, operational tailoring is very different from rebuilding a solution.
Post-launch, most of the work is not about redesigning the solution itself, but about tailoring how it is operationalized within each market. The broader strategic concept often remains unchanged. What changes is how the program is introduced, supported, and embedded within local clinical practice.
This blog features insights from our latest whitepaper, How Pharma Can Use Behavioral Science to Balance Global Strategy with Local Relevance. If you haven’t already, you can access the full whitepaper HERE.
Hear from industry leaders at Astellas Pharma, Merz Therapeutics, Novartis, and S3 Connected Health, as they discuss how pharma organizations build solutions that are globally scalable while remaining relevant across different healthcare systems, regulations, and patient populations.
